bioAffinity Technologies Sees 68.98% Stock Surge

Company Overview

BIOAFFINITY TECHNOLOGIES INC (NASDAQ: BIAF) develops noninvasive diagnostics and targeted therapeutics for lung cancer and related diseases. Founded in 2014 and headquartered in San Antonio, Texas, the company’s flagship product, CyPath® Lung, utilizes flow cytometry and a proprietary porphyrin marker to detect early-stage lung cancer from sputum samples. The test is offered as a laboratory-developed test through Precision Pathology Laboratory Services and aims to improve diagnostic accuracy and reduce unnecessary invasive procedures.

Corporate Structure

With 11 to 50 employees, bioAffinity is led by President and CEO Maria Zannes, who has over 30 years of executive management experience in various sectors. Chief Financial Officer J. Michael Edwards, MBA, CPA, rejoined the company in 2023 after serving as consulting CFO, overseeing strategic finance and commercialization. William Bauta, PhD, serves as Chief Science Officer, contributing more than 25 years of expertise in medicinal chemistry and diagnostic research. The management team is supported by experienced scientists and industry consultants.

Recent Developments and News

On June 2, 2025, bioAffinity filed its Annual Report on Form ARS, detailing ongoing research and development investments and commercialization efforts for CyPath® Lung. In mid-June 2025, the company announced that China’s patent office granted a patent for its “double knockdown” therapeutic strategy, which involves using siRNA to target CD320 and LRP2 receptors in cancer cells. On June 26, 2025, BIAF shares closed at $0.4140, reflecting a 68.98% increase in the previous trading session, with a trading volume of 13,097,498 shares on NASDAQ.

Financial and Strategic Analysis

The Form ARS filing dated June 2, 2025, indicates that bioAffinity continues to allocate a portion of its budget to research and development, particularly toward expanding CyPath® Lung’s clinical applications. While specific revenue and net income figures were not disclosed in the summary, the report emphasizes:

• Ongoing collaborations to encourage test adoption among pulmonologists and oncology centers
• Investment in automated data-analysis platforms to reduce turnaround times
• Cash flow management to support clinical studies and commercialization

Risk factors outlined in the filing include regulatory approval timelines, competitive pressures from imaging modalities, and the need for ongoing financing to fund pipeline programs, including those related to OncoSelect® Therapeutics’ preclinical studies.

Market Position and Industry Context

Lung cancer is a leading cause of cancer-related deaths globally. Current screening protocols rely on low-dose computed tomography (LDCT), which has a high false-positive rate and can lead to invasive follow-up procedures. CyPath® Lung addresses these limitations by offering:

• A noninvasive, at-home sputum collection kit
• High sensitivity and specificity for nodules under 20 mm
• Test results delivered within three days of sample receipt

As a small-cap biotech firm, bioAffinity occupies a niche in early-stage cancer diagnostics. Its flow-cytometry approach differentiates it from competitors focusing on molecular imaging or blood-based biomarkers. The patent grant in China highlights its intent to enter international markets and expand its intellectual property portfolio.

tl;dr

On June 26, 2025, BIAF stock increased by 68.98% to $0.4140 on NASDAQ with trading volume exceeding 13 million shares. Earlier in June, the company’s Annual Report (Form ARS) underscored continued investment in research and development and commercialization of CyPath® Lung. A patent granted in China for the double knockdown siRNA therapy marks progress in therapeutic development. Looking ahead, bioAffinity plans to amplify CyPath® Lung adoption, seek regulatory clearances globally, and advance OncoSelect® Therapeutics into animal studies.